Time course of central nervous dopamine-D2 and 5-HT2 receptor blockade and plasma drug concentrations after discontinuation of quetiapine (Seroquel®) in patients with schizophrenia

Psychopharmacology

Volumn 135, Issue 2, 1998, Pages 119-126

  Gefvert, O ^a   Bergstrom M ^b   Langstrom B ^b   Lundberg, T ^a   Lindstrom L ^a   Yates, R ^c  

^a CENTRAL HOSPITAL   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c ASTRAZENECA   (United Kingdom)

Author keywords

Atypical antipsychotic; Dopamine D2 receptors; PET; Pharmacokinetics; Quetiapine; Serotonin 5HT2 receptor

Indexed keywords

DOPAMINE 2 RECEPTOR; DRUG METABOLITE; QUETIAPINE; RACLOPRIDE; SEROTONIN 2 RECEPTOR;

ADULT; ARTICLE; CENTRAL NERVOUS SYSTEM; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; HUMAN; MALE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SCHIZOPHRENIA;

ADULT; ANIMALS; ANTIPSYCHOTIC AGENTS; AREA UNDER CURVE; BRAIN; CARBON RADIOISOTOPES; DIBENZOTHIAZEPINES; DOPAMINE ANTAGONISTS; HALF-LIFE; HUMANS; MALE; METABOLIC CLEARANCE RATE; RACLOPRIDE; RECEPTORS, DOPAMINE D2; RECEPTORS, SEROTONIN; SALICYLAMIDES; SCHIZOPHRENIA; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0031963279     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002130050492     Document Type: Article

References (28)

1. 11C-raclopride. Psychopharmacology 112: 308-314
2. 2 receptors by the neuroleptic ziprasidone (CP-88,059-01) determined by positron emission tomography. Psychopharmacology 124: 141-147
3. 2 antagonist ritanserin in neuroleptic-induced parkinsonism: a double-blind comparasion with orphenadrine and placebo. Clin Neuropharmacol 13: 500-506
4. Chiodo LA, Bunney BS (1983) Typical and atypical antipsychotics: differential effects of chronic administration on the activity of A9 and A10 midbrain dopaminergic neurons. Neuroscience 3: 1607-1619
5. Delay J, Deniker P, Hart J-M (1952) Traitement des états d'excitation et d'agitation par une méthode medicamenteuse derivées de l'hibernothérapie. Ann Med Psychol 110: 267-73
6. 2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Arch Gen Psychiatry 45: 71-76
7. 2 receptor occupancy during treatment with conventional and atypical neuroleptics. Psychopharmacology 99: S98-S31
8. 2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine: relation to extrapyramidal side effects. Arch Gen Psychiatry 49: 538-544
9. Fleichhacker WW (1995) A multicenter, double-blind, randomised comparison of dose and dose regimen of 'Seroquel' in the treatment of patients with schizophrenia. Abstract ACNP, p 275
10. Goldstein JM, Litwin LC, Sutton EB, Malick JB (1993) Quetiapine: electrophysiological profile of a potential atypical antipsychotic. Psychopharmacology 112: 293-298
11. Goldstein J (1995) Pre-clinical pharmacology of new atypical antipsychotics in late stage development. Exp Opin Invest Drugs 4: 291-298
12. Idänpään HJ, Alhava E, Olkinvora M, Palva I (1977) Agranulocytosis during treatment with clozapine. Eur J Clin Pharmacol 11: 193-198
13. Kane J, Honigfeld G, Singer J, Meltzer H and the Clozaril Collaborative Study Group (1988) Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 45: 789-796
14. Lindström, LH (1988) The effect of long-term treatment with clozapine in schizophrenia; a retrospective study in 96 patients treated with clozapine for up to 13 years. Acta Psychiatr Scand 77: 524-529
15. Litton JE, Holte S, Eriksson L (1990) Evaluation of the Karolinska new positron camera system; the Scanditronix PC2048-15B. IEEE Trans Nucl Sci 37: 743-748
16. 1 binding components of clozapine in the frontal cortex and striatum in the human brain visualised by positron emission tomography. Psychiatr Res Neuroimaging 67: 1-10
17. Malhotra AK, Litman RE, Pickar D (1993) Adverse effects of antipsychotic drugs. Drug Safety
18. Meltzer HY (1992) The importance of serotonin-dopamine interactions in the action of clozapine. Br J Psychiatry 160 [suppl 17]: 22-29
19. 2 affinities differentiate atypical and typical antipsychotic drugs. Psychopharmacol Bull 25: 390-392
20. Migler BM, Warawa EJ, Malick JB (1993) Quetiapine: behavioral effects in conventional and novel tests for atypical antipsychotic drug. Psychopharmacology 112: 299-307
21. Mortimer AM (1994) Newer and older antipsychotics. A comparative review of appropriate use. CNS Drugs 2: 381-396
22. 11C) raclopride binding in healthy young adults and schizophrenic patients Reliability and age effects. Hum Psychopharmacol 7: 157-165
23. 2 receptor occupancy in clozapine treated patients demonstrated by PET. Psychopharmacology 110: 365-367
24. 2-dopamine receptor occupancy in relation to antipsychotic drug effects a double blind PET study of schizophrenic patients. Biol Psychiatry 33: 227-235
25. 2 dopamine receptor occupancy in the living brain. Psychopharmacology 110: 265-272
26. Saller CF, Salama AI (1993) Quetiapine: biochemical profile of a potential atypical antipsychotic. Psychopharmacology 112: 285-292
27. Seeman P, Lee T, Chau-Wong M, Wong K (1976) Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature 261: 717-719
28. White FJ, Wang RY (1983) Differential effects of classical and atypical antipsychotic drugs on A9 and A10 dopamine neurons. Science 221: 1054-1057